Newsroom | 39761 results

GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany, the findings represent one...

VANCOUVER, British Columbia--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced an extension to its option agreement to license the National Research Council of Canada’s (NRC) proprietary nanobody-based CD22 binder for use in Chimeric Antigen Receptor (CAR) therapy. ME Therapeutics will continue developing the CD...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted 2 new employees options to purchase a total of 9,150 shares of the Company’s common stock at an exercise price per share of $23.83, which was the closing pric...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Investor Relations, will participate in a fireside chat and one-on-one investor meetings at Chardan’s 10th Annual Healthcare Conference: The Next 10 Years of Disruptive Innovation, on October 20, 2026. Chardan 10th Annual Healthcare Conference: The Next 10 Years of Disruptive Innovation Date: Tuesday, October 20, 2026 Location:...

LOS ANGELES--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, today announced its inaugural Band As One Los Angeles, a Concert for the Cure, a signature fundraising event that brings together a star-studded lineup of musical artists for an unforgettable night of music, stories and solidarity in support of people facing breast cancer. Paula Abdul will headline the event at the Dolby Theatre and be joined by musical friends who share Komen’s commitment to bringing...

SAN ANTONIO--(BUSINESS WIRE)--BIAF announces closing of $4 million registered direct financing of common stock and private placement priced at-the-market under Nasdaq rules...

ليكسينغتون، ماساتشوستس--(BUSINESS WIRE)--أعلنت Agenus Inc. (المدرجة في بورصة ناسداك بالرمز: AGEN)، الشركة الرائدة في مجال ابتكار العلاجات المناعية للسرطان، اليوم أن وزارة الصحة في جمهورية أرمينيا منحت تراخيص تسويق لكلٍّ من Botvymo® (botensilimab، BOT) وEvamplix® (balstilimab، BAL)، حيث تمت الموافقة على استخدام كل منهما بالاشتراك مع الآخر لعلاج المرضى البالغين المصابين بسرطان القولون والمستقيم النقيلي المستقر ميكروساتليًا (MSS)، الذين لا يعانون من نقائل نشطة في الكبد، وسبق أن تلقوا العلاجات القيا...

ZAMUDIO, Spain--(BUSINESS WIRE)--Oncomatryx, the Basque biopharmaceutical company pioneering the treatment of solid tumors through their microenvironment, has taken part, together with German research institutions, in a study showing in patient tumor tissue that destroying the cells that protect the tumor also kills cancer cells. This was achieved by OMTX305, a bispecific antibody designed by the company that directs the patient’s own T cells against the fibroblasts surrounding the tumor. The w...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device designation (BDD) by the U.S. Food and Drug Administration (FDA). The BDD is designed for novel technologies that enable more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions. Natera’s MCED assay analyzes cell-free DNA in...

マサチューセッツ州レキシントン--(BUSINESS WIRE)--（ビジネスワイヤ） -- アジーナス（Agenus Inc.）（Nasdaq：AGEN）は、免疫腫瘍学分野におけるイノベーションのリーダーで、アルメニア共和国保健省がBotvymo®（ボテンシリマブ、BOT）およびEvamplix®（バルスチリマブ、BAL）を販売承認したと発表しました。両薬剤は、互いに併用する形で、利用可能な標準治療をすでに受けた、活動性肝転移を伴わないマイクロサテライト安定性（MSS）転移性大腸がん（mCRC）の成人患者の治療に使用することがそれぞれ承認されています。両薬剤とも、今回が世界初の販売承認となります。今回の承認は、アルメニア国内の患者に加え、アルメニアの腫瘍専門医の診療のもとで治療を受けるため同国を訪れる患者にも恩恵をもたらすことが期待されています。 ボテンシリマブは、従来の免疫療法への反応がこれまで乏しかった腫瘍においても、自然免疫と獲得免疫による抗腫瘍免疫応答を活性化するよう設計されたFc機能強化型の多機能抗CTLA-4抗体です。バルスチリマブは、抗腫瘍T細胞活性を持続させるよう設...